Clinical Trial Update: Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated Sunitinib malate in iodine-refractory thyroid cancers, including differentiated and medullary subtypes. Results were posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Follicular Thyroid Carcinoma
• Medullary Thyroid Carcinoma
• Oncocytic Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Thyroid Carcinoma
• Unresectable Thyroid Carcinoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-15